Allogene Therapeutics Inc
(ALLO)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2019 | 12-2018 | 12-2017 | 12-2006 | |
| Assets | ||||
| Current Assets | ||||
| Cash & Cash Equivalents | 175,126 | 92,432 | N/A | N/A |
| Marketable Securities | 355,407 | 366,952 | N/A | N/A |
| TOTAL | $544,576 | $467,982 | $N/A | $N/A |
| Non-Current Assets | ||||
| PPE Net | 56,449 | 8,595 | N/A | N/A |
| Investments And Advances | 63,214 | 261,966 | 0 | 0 |
| Intangibles | 151 | 754 | 0 | 0 |
| Other Non-Current Assets | 53,412 | 34,558 | 0 | 0 |
| TOTAL | $173,226 | $305,873 | $N/A | $N/A |
| Total Assets | $717,802 | $773,855 | $N/A | $N/A |
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts payable and accrued liabilities | 9,250 | 12,338 | 0 | 0 |
| Accrued Expenses | 23,829 | 17,121 | 2 | N/A |
| TOTAL | $33,079 | $29,459 | $2 | $N/A |
| Non-Current Liabilities | ||||
| Other Non-Current Liabilities | 55,700 | 41,232 | 0 | 0 |
| TOTAL | $55,700 | $41,232 | $N/A | $N/A |
| Total Liabilities | $88,779 | $70,691 | $2 | $N/A |
| Shareholders' Equity | ||||
| Shares Outstanding, K | 124,907 | 121,483 | N/A | N/A |
| Common Shares | 124 | 121 | 26 | N/A |
| Retained earnings | -396,122 | -211,528 | -23 | N/A |
| Other shareholders' equity | 1,145 | 306 | -5 | 0 |
| TOTAL | $629,023 | $703,164 | $-2 | $N/A |
| Total Liabilities And Equity | $717,802 | $773,855 | $0 | $0 |